Last reviewed · How we verify

NCT04915235: PAPCAT

Prevalence and Prognosis of Cardiac Amiloidosis in Turkey

Status unknown Last updated 7 June 2021
What this trial tests

trial testing Algorithm in Cardiac Amyloidosis in 2,087 participants. Status unknown.

Timeline
18 September 2020
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorTurkish Society of Cardiology
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment2,087
Start date18 September 2020
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Turkish Society of Cardiology

Who can join

18 and older, any sex, with Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with left ventricular hypertrophy are further examined according to an algorithm to check if they have a cardiac amyloidosis

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Algorithm

Trials testing the same drug.

Other recruiting trials for Cardiac Amyloidosis

Currently open trials in the same condition.

Other Turkish Society of Cardiology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04915235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing